Improved Survival with Bevacizumab in Advanced Cervical Cancer

BACKGROUND: Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical canc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tewari, Krishnansu S., Sill, Michael W., Long, Harry J., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., Monk, Bradley J.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010094/
https://ncbi.nlm.nih.gov/pubmed/24552320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1309748
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares